Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amrutanjan Health CareBOM:590006 -0.70%71 Interest Coverage is 52.36 as of Jun. 2026, which is 78% below its 10-year median of 239.02. GuruFocus rates BOM:590006 with a GF Score™ of 71/100 and a GF Value™ of ₹827.69 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 678 Drug Manufacturers companies, Amrutanjan Health Care ranks better than 88.2% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Amrutanjan Health Care's
Operating Income
for the
three
months ended in Jun. 2026 was ₹23 Mil. Amrutanjan Health Care's Interest Expense for the
three
months ended in Jun. 2026 was ₹-0 Mil.
Amrutanjan Health Care's interest coverage for the quarter that ended in Jun. 2026 was 52.36.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Amrutanjan Health Care Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Amrutanjan Health Care's Interest Coverage or its related term are showing as below:
BOM:590006'
s Interest Coverage Range Over the Past 10 Years
Min: 121.69 Med: 239.02 Max: 545.58
Current: 304.92
BOM:590006's Interest Coverage is ranked better than 88.2% of 678
companies
in the Drug Manufacturers industry
Industry Median: 12.575
vs BOM:590006: 304.92
Amrutanjan Health Care (BOM:590006) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Amrutanjan Health Care Interest Coverage Related Terms
Amrutanjan Health Care Interest Coverage Historical Data
* Premium members only.
The historical data trend for Amrutanjan Health Care's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Amrutanjan Health Care's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amrutanjan Health Care Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amrutanjan Health Care's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Amrutanjan Health Care's Interest Coverage falls into.
Amrutanjan Health Care Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amrutanjan Health Care (BOM:590006) has a Interest Coverage of 52.36 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Amrutanjan Health Care and its competitors. This is 78% below median its historical median of 239.02. Over the past decade, Amrutanjan Health Care's Interest Coverage has ranged from 121.69 to 545.58. According to the industry distribution chart, Amrutanjan Health Care ranks #80 out of 678 companies in the Drug Manufacturers industry, placing it in the top 11.8%.
Is Amrutanjan Health Care's Interest Coverage too high?
Amrutanjan Health Care's current Interest Coverage of 52.36 is 78% below median its 10-year median of 239.02. Over the past 10 years, this metric has ranged from a low of 121.69 to a high of 545.58. The Drug Manufacturers industry median Interest Coverage is 12.58. Amrutanjan Health Care's value of 52.36 is 316.4% above this industry median. Based on the distribution chart, Amrutanjan Health Care ranks #80 out of 678 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amrutanjan Health Care has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amrutanjan Health Care's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Amrutanjan Health Care ranks #80 out of 678 companies for Interest Coverage. This places Amrutanjan Health Care in the top 12% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.58. Amrutanjan Health Care's value of 52.36 is 316.4% above this benchmark. Historically, Amrutanjan Health Care's own Interest Coverage has ranged from 121.69 to 545.58 over the past decade. While the company's 10-year median is 239.02 vs. the industry median of 12.58, Amrutanjan Health Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.58, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amrutanjan Health Care's current Interest Coverage of 52.36 is 316.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Amrutanjan Health Care and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amrutanjan Health Care's current Interest Coverage is 52.36, which is 78% below median its own 10-year median of 239.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amrutanjan Health Care stock overvalued right now?
Based on GuruFocus' analysis, Amrutanjan Health Care (BOM:590006) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹827.69, compared to a current price of ₹490.35 — trading 40.8% below its estimated fair value. The current Interest Coverage is 52.36, which is 78% below median its 10-year median of 239.02 and 316.4% above the Drug Manufacturers industry median of 12.58. Amrutanjan Health Care's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Amrutanjan Health Care (BOM:590006), the current Interest Coverage is 52.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amrutanjan Health Care (BOM:590006) Overvalued in 2026?
Based on GuruFocus' analysis, Amrutanjan Health Care stock appears to be undervalued.
The current stock price of ₹490.35 is trading 40.8% below its estimated GF Value™ of ₹827.69.
GuruFocus considers Amrutanjan Health Care to be Significantly Undervalued.
Key valuation signals for BOM:590006:
Interest Coverage: 52.36 (78% below median its 10-year median of 239.02)
GF Value™: ₹827.69 vs. price of ₹490.35 (40.8% below fair value)
Industry Position: 316.4% above the Drug Manufacturers median (#80 of 678)
No single metric tells the full story. See the BOM:590006 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amrutanjan Health Care Ltd manufactures Ayurvedic and allopathic products. The company operates through the following segments: OTC Products, Beverages, and Others. The majority of the revenue is generated from its OTC segment which is engaged in the manufacturing products of pain management, congestion management, and hygiene. Its beverage segment includes manufacturing fruit juices and oral rehydration drinks. Some of its products include Roll-on, Spray, Balm, Cough Syrup, Sanitary napkins, and inhalers. Geographically, it generates the majority of the revenue from India.
71GF Score
Get the complete analysis for BOM:590006
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:590006 has been successfully added to your 
